annual cash & cash equivalents:
$2.58B-$449.56M(-14.86%)Summary
- As of today (August 17, 2025), TAK annual cash & cash equivalents is $2.58 billion, with the most recent change of -$449.56 million (-14.86%) on March 1, 2025.
- During the last 3 years, TAK annual cash & cash equivalents has fallen by -$4.43 billion (-63.21%).
- TAK annual cash & cash equivalents is now -84.79% below its all-time high of $16.93 billion, reached on March 31, 2008.
Performance
TAK Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$2.42B-$152.35M(-5.92%)Summary
- As of today (August 17, 2025), TAK quarterly cash & cash equivalents is $2.42 billion, with the most recent change of -$152.35 million (-5.92%) on June 1, 2025.
- Over the past year, TAK quarterly cash & cash equivalents has dropped by -$2.58 billion (-51.55%).
- TAK quarterly cash & cash equivalents is now -76.92% below its all-time high of $10.49 billion, reached on March 31, 2011.
Performance
TAK quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TAK Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -14.9% | -51.5% |
| 3 y3 years | -63.2% | -48.8% |
| 5 y5 years | -56.4% | -55.8% |
TAK Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -63.2% | at low | -59.7% | +18.4% |
| 5 y | 5-year | -70.5% | at low | -72.4% | +18.4% |
| alltime | all time | -84.8% | +48.6% | -76.9% | +18.4% |
TAK Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $2.42B(-5.9%) |
| Mar 2025 | $2.58B(-14.9%) | $2.57B(-18.2%) |
| Dec 2024 | - | $3.15B(-47.7%) |
| Sep 2024 | - | $6.01B(+20.4%) |
| Jun 2024 | - | $5.00B(+65.2%) |
| Mar 2024 | $3.02B(-24.5%) | $3.02B(+47.9%) |
| Dec 2023 | - | $2.04B(-4.0%) |
| Sep 2023 | - | $2.13B(-2.6%) |
| Jun 2023 | - | $2.18B(-45.4%) |
| Mar 2023 | $4.01B(-42.7%) | $4.00B(-23.4%) |
| Dec 2022 | - | $5.23B(-5.4%) |
| Sep 2022 | - | $5.52B(+16.8%) |
| Jun 2022 | - | $4.73B(-32.1%) |
| Mar 2022 | $7.00B(-19.9%) | $6.96B(+10.6%) |
| Dec 2021 | - | $6.29B(+15.9%) |
| Sep 2021 | - | $5.43B(-8.3%) |
| Jun 2021 | - | $5.92B(-32.4%) |
| Mar 2021 | $8.74B(+48.0%) | $8.76B(+46.3%) |
| Dec 2020 | - | $5.99B(+0.3%) |
| Sep 2020 | - | $5.97B(+8.9%) |
| Jun 2020 | - | $5.48B(-7.1%) |
| Mar 2020 | $5.91B(-6.9%) | $5.90B(+13.1%) |
| Dec 2019 | - | $5.22B(+3.7%) |
| Sep 2019 | - | $5.03B(-8.5%) |
| Jun 2019 | - | $5.50B(-13.1%) |
| Mar 2019 | $6.34B(+79.8%) | $6.33B(+134.6%) |
| Dec 2018 | - | $2.70B(-3.2%) |
| Sep 2018 | - | $2.79B(+33.2%) |
| Jun 2018 | - | $2.09B(-24.4%) |
| Mar 2018 | $3.53B(+4.5%) | $2.77B(-29.0%) |
| Dec 2017 | - | $3.91B(+2.0%) |
| Sep 2017 | - | $3.83B(-0.7%) |
| Jun 2017 | - | $3.86B(+35.1%) |
| Mar 2017 | $3.38B(-32.3%) | $2.86B(-40.6%) |
| Dec 2016 | - | $4.81B(-21.4%) |
| Sep 2016 | - | $6.12B(+8.1%) |
| Jun 2016 | - | $5.66B(+40.9%) |
| Mar 2016 | $4.98B(-16.2%) | $4.02B(-13.7%) |
| Dec 2015 | - | $4.66B(-8.2%) |
| Sep 2015 | - | $5.07B(+8.0%) |
| Jun 2015 | - | $4.70B(-13.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | $5.95B(-28.0%) | $5.43B(-16.9%) |
| Dec 2014 | - | $6.54B(+5.0%) |
| Sep 2014 | - | $6.23B(+1.4%) |
| Jun 2014 | - | $6.14B(-5.1%) |
| Mar 2014 | $8.26B(+38.3%) | $6.47B(+53.9%) |
| Dec 2013 | - | $4.21B(+16.7%) |
| Sep 2013 | - | $3.60B(+33.0%) |
| Jun 2013 | - | $2.71B(-53.2%) |
| Mar 2013 | $5.98B(+7.9%) | $5.79B(+90.0%) |
| Dec 2012 | - | $3.05B(+11.4%) |
| Sep 2012 | - | $2.74B(+5.8%) |
| Jun 2012 | - | $2.59B(-53.1%) |
| Mar 2012 | $5.54B(-47.5%) | $5.52B(+122.6%) |
| Dec 2011 | - | $2.48B(-23.4%) |
| Sep 2011 | - | $3.24B(+36.7%) |
| Jun 2011 | - | $2.37B(-77.4%) |
| Mar 2011 | $10.55B(+11.6%) | $10.49B(+342.4%) |
| Dec 2010 | - | $2.37B(-10.5%) |
| Sep 2010 | - | $2.65B(+2.0%) |
| Jun 2010 | - | $2.60B(-8.9%) |
| Mar 2010 | $9.45B(+23.0%) | $2.85B(-3.7%) |
| Dec 2009 | - | $2.96B(+2.0%) |
| Sep 2009 | - | $2.90B(+25.1%) |
| Mar 2009 | $7.68B(-54.6%) | $2.32B(-5.5%) |
| Dec 2008 | - | $2.45B |
| Mar 2008 | $16.93B(+11.1%) | - |
| Mar 2007 | $15.24B(-3.1%) | - |
| Mar 2006 | $15.73B(+10.6%) | - |
| Mar 2005 | $14.23B(+11.9%) | - |
| Mar 2004 | $12.71B(+29.3%) | - |
| Mar 2003 | $9.84B(+38.5%) | - |
| Mar 2002 | $7.10B(+23.0%) | - |
| Mar 2001 | $5.77B(-7.3%) | - |
| Mar 2000 | $6.23B(+36.4%) | - |
| Mar 1999 | $4.56B(+29.6%) | - |
| Mar 1997 | $3.52B(-3.8%) | - |
| Mar 1996 | $3.66B(-10.1%) | - |
| Mar 1995 | $4.07B(+22.4%) | - |
| Mar 1994 | $3.32B(+29.2%) | - |
| Mar 1993 | $2.57B(+23.7%) | - |
| Mar 1992 | $2.08B(+20.0%) | - |
| Mar 1991 | $1.73B | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly cash & cash equivalents year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents?
The current annual cash & cash equivalents of TAK is $2.58B
What is the all time high annual cash & cash equivalents for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash & cash equivalents is $16.93B
What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents year-on-year change?
Over the past year, TAK annual cash & cash equivalents has changed by -$449.56M (-14.86%)
What is Takeda Pharmaceutical Company Limited quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of TAK is $2.42B
What is the all time high quarterly cash & cash equivalents for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash & cash equivalents is $10.49B
What is Takeda Pharmaceutical Company Limited quarterly cash & cash equivalents year-on-year change?
Over the past year, TAK quarterly cash & cash equivalents has changed by -$2.58B (-51.55%)